Select a community
Parkinson's
Find out more about the PatientsLikeMe
Parkinson's Community
Home > Community Treatment Reports > Valsartan Treatment Report
What is Valsartan?

Valsartan is an angiotensin II receptor antagonist used in the treatment of high blood pressure, of congestive heart failure (CHF), and post-myocardial infarction (MI). Read more...Click to read more below

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell 		# of patients evaluated by
High blood pressure (Hypertension) 4 0
Other 2 1
proteinuria 1 0

See all 7 patients currently taking Valsartan

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
1 100%
Moderate
0 0%
Mild
0 0%
None
0 0%

Most commonly reported side effects

Orthostatic/Postural Hypotension
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  40 mg daily 80 mg daily 160 mg daily 320 mg daily
  1 Number of Patients: 1 3 Number of Patients: 3 2 Number of Patients: 2 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Valsartan (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe
1 100% Side effects too severe: 100%

See all 1 patient who’ve stopped taking Valsartan

Duration See details about how long patients take this treatment ▼

Currently Taking Valsartan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Valsartan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
0 0%
Usually
1 100%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on March 22, 2010.